posteditor

B LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B PARIS, April 27, 2026 /PRNewswire/ — A new study has established that treatment with essential phospholipids (Essentiale) resulted in a 2.5 times greater reduction in… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B Wagner Brings More Than 25 Years of Experience and a Distinguished Track Record with Respected Tire Companies ATLANTA, April 27, 2026 /PRNewswire/ — Kumho Tire… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B GUANGZHOU, China, April 27, 2026 /PRNewswire/ — HUYA Inc. (“Huya” or the “Company”) (NYSE: HUYA), a leading game-related entertainment and services provider, today announced… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B Launching this May, Portrait TV debuts 3,000+ hours of culture-driving, creator-led programming—including The Shop and On The Radar. MIAMI, April 27, 2026 /PRNewswire/ —… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B The Reconciliation Shield™ is the first formalized business debt relief program designed to lower merchant cash advance payments before default, using reconciliation written into… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B MORRIS PLAINS, N.J., April 27, 2026 /PRNewswire/ — Solstice Advanced Materials (NASDAQ: SOLS), today announced that its Board of Directors has declared a regular… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B Accepting submissions until May 25 | Featured Voices to Help Open the Day Nationwide Beginning July 4 NEW YORK, April 26, 2026 /PRNewswire/ — After… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B Ajax’s lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B In an increasingly digital world, L.L.Bean has been inviting people to rediscover the power of getting outside during Mental Health Month—and this year, the… Login to continue reading Login Sign up for complimentary access Sign Up Now Close